RxDoctor Payments Data

Saleem Husain, MD

Cardiovascular Disease · Plainfield, NJNPI 1134197346

Payments from drug & device makers

$78,047in general payments, 2019–2025

Across 1,068 payments — averaging $73.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Shockwave Medical, Inc$15K
  • Penumbra, Inc.$12K
  • Abbott$6K
  • Inari Medical, Inc.$5K
  • Medtronic$4K
  • plus $18K from 47 others

What the payments were for

  • Consulting fees$3,3004%
  • Speaking & faculty fees$27,45035%
  • Travel & lodging$11,93315%
  • Food & beverage$35,32545%
  • Education$100%
  • Other$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,047 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,061,396
Medicare patients
2,438
Services billed
9,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban685$667,765
EntrestoSacubitril/Valsartan237$244,011
BrilintaTicagrelor292$231,858
XareltoRivaroxaban175$194,437
MultaqDronedarone Hcl32$55,995
FarxigaDapagliflozin Propanediol37$35,518
VerquvoVericiguat19$33,236
Ranolazine ErRanolazine215$24,602
Praluent PenAlirocumab21$22,524
Repatha SyringeEvolocumab18$19,783
Repatha SureclickEvolocumab19$19,389
Metoprolol Succinate1,181$17,996
Repatha PushtronexEvolocumab20$17,559
Icosapent Ethyl25$16,233
JardianceEmpagliflozin15$11,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$504$667,765685 claims
AstraZenecaBrilinta, Farxiga$17,640$267,376329 claims
NovartisEntresto$1,059$244,011237 claims
Johnson & JohnsonXarelto$434$194,437175 claims
Sanofi-aventis U.S. LLCMultaq$373$55,99532 claims
MerckVerquvo$690$33,23619 claims
Boehringer IngelheimJardiance$129$11,70515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Plainfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →